Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: a retrospective case-control study

Clicks: 315
ID: 267937
2007
Free PDF
Article Quality & Performance Metrics
Overall Quality Improving Quality
0.0 /100
Combines engagement data with AI-assessed academic quality
AI Quality Assessment
Not analyzed
Abstract
Oseltamivir prophylaxis appeared to be safe and well tolerated in managing an influenza outbreak in an HSCT outpatient residence.
Reference Key
d2007clinicalsafety Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Vu D;Peck AJ;Nichols WG;Varley C;Englund JA;Corey L;Boeckh M;;
Journal Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Year 2007
DOI
DOI not found
URL
http://www.ncbi.nlm.nih.gov/pubmed/17578777
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE humans pubmed abstract nih national institutes of health national library of medicine treatment outcome research support non-u.s. gov't adult female male N.I.H. Extramural adolescent aged middle aged Child Drug Administration Schedule Retrospective Studies follow-up studies reference values immunocompromised host case-control studies dose-response relationship drug human / immunology risk assessment antiviral agents / therapeutic use* probability influenza antiviral agents / adverse effects hematopoietic stem cell transplantation* human / prevention & control* pmid:17578777 doi:10.1086/518985 debie vu angela j peck michael boeckh graft rejection graft survival hematologic neoplasms / diagnosis hematologic neoplasms / immunology hematologic neoplasms / therapy* oseltamivir / adverse effects oseltamivir / therapeutic use*

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.